10X Genomics Inc vs Viatris Inc — how do they compare? 10X Genomics Inc trades at $46.82 (market cap $5.48B), while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 3.6× 10X Genomics Inc's market cap, and Viatris Inc pays a 2.83% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | VTRS | |
|---|---|---|
Market Cap | $5.48B | $19.79B |
Sector | Health | Health |
52-Week High | $45.80 | $17.39 |
52-Week Low | $11.34 | $8.74 |
Enterprise Value | $5.02B | $32.00B |
Dividend Yield | — | 2.83% |
Trailing returns across standard periods
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →